Imatinib Krka (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. This inhibition prevents phosphorylation of downstream signaling proteins, halting the uncontrolled cell division that characterises the targeted malignancies.

The dose of Imatinib Krka is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. No standard dosing regimen is provided here; the prescriber determines the appropriate amount.

Safety data for Imatinib in pregnancy and lactation are limited. Because potential risks to the fetus or infant cannot be excluded, the drug is generally avoided unless the therapeutic benefit justifies the potential hazard. Consultation with a specialist is essential.

To order Imatinib Krka, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Imatinib is the first‑generation BCR‑ABL tyrosine‑kinase inhibitor. Newer agents such as dasatinib and nilotinib are also approved for chronic myeloid leukemia and may offer faster molecular responses or activity against certain resistant mutations, but they can have different safety profiles. Choice of therapy depends on mutation status, comorbidities, and physician judgment.

Imatinib Krka should be stored below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposure to extreme temperatures or humidity.

Imatinib Krka is taken orally, usually with a glass of water. It can be swallowed with or without food; however, a consistent approach (with or without meals) is recommended to maintain stable drug levels.

The most serious risks include severe neutropenia or other blood‑cell abnormalities, hepatotoxicity (significant liver enzyme elevation or hepatitis), cardiac failure, pulmonary hypertension, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for these events.

Imatinib Krka should be avoided in individuals with known hypersensitivity to imatinib or any of its excipients, in patients with severe hepatic impairment, and in those for whom the risk‑benefit ratio is unfavorable, such as certain pregnant or breastfeeding women unless absolutely necessary.